Study finds "weak alignment" between industry and policy leaders

Share this article:
Study finds "weak alignment" between industry and policy leaders
Study finds "weak alignment" between industry and policy leaders

APCO Worldwide and its research consultancy APCO Insight released its “State of the U.S. Biopharmaceutical Industry 2013,” today. The report evaluates the industry's relationships, or “Return on Reputation (ROR)”—a metric developed by the firm—with key industry stakeholders.

The report found that the industry's score was relatively stable among most stakeholders, but cautioned of a trending decline among policy leaders. The group also raised concerns about responsible marketing, especially to physicians.

Researchers found a modest decrease, which it did not attribute any statistical significance to, in the group's “reputation index score” for HCPs and opinion leaders, as well as a slight tumble in the overall reputation index score from 61.3 in 2012 to 60.5 in 2013.

The group defines reputation index as a “reliable measure of the industry's overall reputation that takes into account” a number of factors including 54 “stakeholder-defined attributes,” such as sustainable innovation, pharmacovigiliance, chronic disease management and patient assistance.

It also states that a “one-point increase” in “reputation index translates into,” a .13% increase in market cap, 1.1% increase in sales for the average biopharma company and an increase of more than 550,000 patients who are likely to ask their doctor about a company's medicine, among others.

The most drastic fall was seen among policy leaders, dropping from 58.6 to 55.3 (on a scale of 100) from 2012 to 2013. Rep. Henry Waxman's letter to Gilead CEO John Martin over Sovaldi's pricing stands as one of the more recent, and notable, pushbacks against industry in recent memory,.  

“The U.S. Biopharmaceutical industry's Reputation index scores remains stable from 2012, with no statistically significant changes among key stakeholder groups; however, a decline may be emerging among Policy Leaders as a gradual, directional decline is noticeable,” researchers wrote.

The report advises that that a “weak alignment presents clear opportunities to strengthen image,” and “while performance remains stable on Executive Engagement, impact has directionally declined, pushing up Social Responsibility expectations (Patient Assistance, Philanthropy, and Reliability.”

The survey also covers a “Reputation Matrix,” which maps 28 reputation drivers by their impact. The matrix illustrates that the industry faces key vulnerabilities in affordability, pricing transparency, executive management, and governance.

The industry's core assets, according to the group's research, are “defined by the functional attributes of its products (product safety, manufacturing and product transparency).”

It was also noted that “concerns about responsible marketing persist—especially marketing to physicians—and elevate the importance of Responsible Business Operations.” Given the recent widespread allegations of bribery by GSK in China, these concerns should come as little surprise.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...